Aptorum Group (APM)

Executive Summary

Aptorum Group (NASDAQ: APM) is a Hong Kong-based clinical-stage biopharmaceutical company focused on oncology and infectious diseases. The company’s pipeline includes ALS-4, a small molecule for Staphylococcus aureus infections (including MRSA), which has completed a Phase 1 healthy volunteer study (NCT05274802), and NCL-195, a preclinical candidate for neuroblastoma. Despite a low market capitalization of ~$6.7 million, Aptorum has demonstrated clinical execution with ALS-4 moving beyond preclinical. The company also completed a Phase 1 study for SACT-1, another candidate currently undisclosed in their public pipeline. With limited financial resources and early-stage assets, Aptorum's near-term value hinges on advancing ALS-4 into Phase 2 efficacy trials and progressing NCL-195 toward an IND filing.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 initiation of ALS-4 for MRSA infections35% success
• Q1 2027IND submission for NCL-195 in neuroblastoma20% success
• Q2 2027Licensing or partnership deal for pipeline assets25% success